A Study of Carbon-14-Labeled [14C]-LY3549492 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 3, 2024

Primary Completion Date

February 15, 2024

Study Completion Date

February 15, 2024

Conditions

Healthy Male

Interventions

DRUG

[14C]-LY3549492

Administered as oral solution.

DRUG

LY3549492

Administered orally.

DRUG

[14C]-LY3549492

Administered as IV infusion.

Trial Locations (1)

Fortrea Clinical Research Unit, Holbeck

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT06194500 - A Study of Carbon-14-Labeled [14C]-LY3549492 in Healthy Participants | Biotech Hunter | Biotech Hunter